NCCN.com - Evidence-Based Cancer Guidelines and Treatment Summaries for Patients (sundry topics)

NCCN.com - Evidence-Based Cancer Guidelines and Treatment Summaries for Patients

NCCN.com Puts the Focus on Living With Cancer...
	Understanding Early Introduction of Palliative Care Options		Intimacy and Sexual Issues for Patients Undergoing Cancer Treatment
	Making the Transition From Hospital to Home: IV Care		Making the Transition From Hospital to Home: Managing Feeding, Medication, and Infection
	VIDEO: How to Maintain Good Bone Health During Cancer Treatment		VIDEO: Cardiotoxicity: A Common Side Effect of Chemotherapy

NCCN Guidelines: Ovarian Cancer March 2012

Blogger's Note: the pdf link below requires registration (free), alternatively go to: http://www.nccn.org and click on guidelines 3/2012 version shows (pages 4/5) changes from 2/2012  version; most recent version includes 'language' changes, category recommendations (eg. highly recommended, neoadjuvant therapy, CA125/clinical relapse/re-treatment, LMP, fertility issues, 'malignant' sex chord stromal, stage 1 added (stages 11-1V) to certain pages....) 

NCCN Guidelines: Ovarian Cancer 2012

Guidelines needed to address cancer survivorship care, says oncologist - NCCN conference

Guidelines needed to address cancer survivorship care, says oncologist

A medical oncologist from the prestigious Fox Chase Cancer Center presented an argument at the ongoing National Comprehensive Cancer Network's 17th Annual Conference that, in light of people with cancer who are living much longer than ever, that they have special health needs that ought to be addressed by national standards of care.

Cancer survivors face a lot of unique and very specific challenges," says Crystal S. Denlinger, M.D., from Fox Chase Cancer Center. "In oncology medicine, there has been a much more concerted effort to address these needs in a systematic way."

For the last five years Denlinger has been the driving force at Fox for the establishment of of such guidelines, developing the Center for Survivorship at Fox Chase to address this for patients of that cancer center.

Together with colleagues from other NCCN institutions, Denlinger would like to see cancer accreditation organizations include survivorship care plans in their accreditation requirements.
Source: NCCN

NCCN Annual Conference: Clinical Practice Guidelines & Quality Cancer Care March 14-18 Florida

eg:

Clinical Practice Decisions in Ovarian Cancer

Roundtable Discussion - Optimal Care for Patients: Who Decides?

Clinical Practice Decisions in Treating the Adolescent and Young Adult with Cancer

Clinical Practice Decisions in CNS (central nervous system) Metastases  

Sunday Brunch with the Experts (the patients??): Issues in Cancer Survivorship 

audio: NCCN Ovarian Cancer Guidelines Update 2011

Blogger's Note: requires registration

National Comprehensive Cancer Network - New Paradigms in Advanced Ovarian Cancer CME - Dr Deborah K. Armstrong (repeat post)

Note: requires registration to view (free)

New Paradigms in Advanced Ovarian Cancer
Presented by:                       Deborah K. Armstrong,  MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins   Supported by educational grants from Centocor Ortho Biotech and Genentech BioOncology.

P\S\L - News: CA-125 Monitoring Fails to Make Decisions Easier for Treatment of Ovarian Cancer: Presented at NCCN

(NCCN) Updated Ovarian Cancer Guidelines Offer a New Treatment Choice

Note: this refers to the Japanese study published 2010 of weekly Taxol - search blog for the original study and additional commentaries


March 14, 2011 — The updated 2011 National Comprehensive Cancer Network (NCCN) Ovarian Cancer Guidelines have added a new treatment option — dose-dense paclitaxel — for the first-line treatment of stage II, III, or IV epithelial ovarian cancer.

The category 1 recommendation comes from data from the Japanese Gynecologic Oncology Group, said panel chair Robert J. Morgan, MD, professor of medicine at the City of Hope Comprehensive Cancer Center in Duarte, California, here at the NCCN 16th Annual Conference.

In a phase 3 open-label randomized controlled trial published in the Lancet (2009; 374:1331-1338), Noriyuki Katsumata and colleagues reported that dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer resulted in a significant survival advantage. The study concluded that paclitaxel and carboplatin given every 3 weeks is standard treatment for advanced ovarian carcinoma.

"This was an important addition," Dr. Morgan told Medscape Medical News........"

abstract: Development and Validation of 11 Symptom Indexes to Evaluate Response to Chemotherapy for Advanced Cancer

Abstract

Recent guidance from the FDA discusses patient-reported outcomes as end points in clinical trials. Using methods consistent with this guidance, the authors developed symptom indexes for patients with advanced cancer. Input on the most important symptoms was obtained from 533 patients recruited from NCCN Member Institutions and 4 nonprofit social service organizations. Diagnoses included bladder, brain, breast, colorectal, head and neck, hepatobiliary/pancreatic, kidney, lung, ovarian, and prostate cancers and lymphoma. Physician experts in each of these diseases were also surveyed to differentiate symptoms that were predominantly disease-based from those that were predominantly treatment-induced. Results are evaluated alongside previously published indexes for 9 of these 11 advanced cancers that were created based on expert provider surveys, also implemented at NCCN Member Institutions. Final results are 11 symptom indexes that reflect the highest priorities of people affected by these 11 advanced cancers and the experienced perspective of the people who provide their medical treatment. Beyond the clinical value of such indexes, they may also contribute significantly to satisfying regulatory requirements for a standardized tool to evaluate drug efficacy with respect to symptomatology.

NCCN Guidelines for Patients™ Breast Cancer

Breast Cancer

NCCN Guidelines for Patients™ - Ovarian Cancer

Ovarian Cancer

Level of Scientific Evidence Underlying Recommendations Arising From the National Comprehensive Cancer Network Clinical Practice Guidelines — JCO

Conclusion: Recommendations issued in the NCCN guidelines are largely developed from lower levels of evidence but with uniform expert opinion. This underscores the urgent need and available opportunities to expand evidence base in oncology.

NCCN Educational Opportunities - Webinar: An Overview of Gynecologic Malignancies Dept 17th

Educational Events & Programs

NCCN Oncology Case Management Program™ Webinar: An Overview of Gynecologic Malignancies

Friday, September 17, 2010 (On-line)
12:30 PM – 2:00 PM

NCCN Receives $4 Million in Oncology Research Funding from GlaxoSmithKline

"Pazopanib is currently approved by the FDA to treat patients with advanced renal cell carcinoma. The research grant to NCCN will evaluate the effectiveness of pazopanib in solid tumors including renal, sarcoma, thyroid, neuroendocrine, and ovarian cancers."

full free access: Practice and Productivity of Physician Assistants and Nurse Practitioners in Outpatient Oncology Clinics at National Comprehensive Cancer Network Institutions — JOP

NCCN: online survey regarding patient assistance programs

NCCN Trends is a tool to help assess the opinions and habits of oncology patients, caregivers, case managers, and other groups.  This survey includes questions about patient assistance programs.  Results from this survey will help NCCN and the oncology community develop patient assistance programs and tools.

To participate in this month's survey, click:
http://www.surveymonkey.com/s.aspx?sm=Gjm3p1VQ7MPKULplsmwhTQ_3d_3d 

Answering the questions should take less than five minutes. Submit your answers by August 18, and by September 18, all responders will find out what the most common answers were for each question.  Only those individuals who participate will receive the results. All responses will be kept completely anonymous.

Please note that the aggregate results of the survey may be used with third party collaborators, including those individuals who participate in the survey. The results will always be presented ONLY in the format of an aggregated data report where the responses and identification of individual responders will not be possible. 

If you do not wish to receive further e-mails through SurveyMonkey related to NCCN Trends surveys or any other NCCN surveys, please click here: 


NCCN Trends 
National Comprehensive Cancer Network 
275 Commerce Drive, Suite 300 
Fort Washington, PA 19034 
+1 (215) 690-0300 

updated (annual) February 2010: NCCN Clinical Practice Guidelines in Oncology

Note: the NCCN website requires registration/password but is free. It is an excellent resource for ovarian cancer(s) as well as genetic syndrome guidelines.

Page 4 indicates changes over prior guidelines.

Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer - media item

NCCN updates their guidelines annually - the guidelines on a variety of subjects (cancers/genetics etc) can be found at: http://www.nccn.org
Access requires registration but is free. There is a specific area for the genetics of breast/ovarian but to find genetics relating to Lynch Syndrome you need to go to the colorectal cancer section.